{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:46:49Z","timestamp":1790801209472,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.molimm.2017.02.011","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T04:04:16Z","timestamp":1488773056000},"page":"166-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Alum adjuvanted rabies DNA vaccine confers 80% protection against lethal 50 LD50 rabies challenge virus standard strain"],"prefix":"10.1016","volume":"85","author":[{"given":"Rajni","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molimm.2017.02.011_bib0005","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0140-6736(04)17223-1","article-title":"Efficacy of the RTS, S\/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial","volume":"364","author":"Alonso","year":"2004","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.molimm.2017.02.011_bib0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0264-410X(97)00147-3","article-title":"Epitope specificity of antibodies raised against enterotoxigenic Escherichia coli CFA\/I fimbriae in mice immunized with naked DNA","volume":"16","author":"Alves","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2017.02.011_bib0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4269\/ajtmh.2011.10-0110","article-title":"Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants","volume":"84","author":"Ar\u00e9valo-Herrera","year":"2011","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.molimm.2017.02.011_bib0020","doi-asserted-by":"crossref","first-page":"P428","DOI":"10.1186\/2051-1426-3-S2-P428","article-title":"Safety data of Montanide ISA 51 VG and Montanide ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines","volume":"3","author":"Ascarateil","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molimm.2017.02.011_bib0025","article-title":"The Theory and Practical Application of Adjuvants","author":"Asherson","year":"1995"},{"key":"10.1016\/j.molimm.2017.02.011_bib0030","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/S0140-6736(16)31729-9","article-title":"The fight against rabies: the Middle East needs to step up its game","volume":"388","author":"Baghi","year":"2016","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.molimm.2017.02.011_bib0035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/14712598.8.2.235","article-title":"Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients","volume":"8","author":"Beran","year":"2008","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.molimm.2017.02.011_bib0040","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2105\/AJPH.74.5.503","article-title":"Intradermal immunization with human diploid cell rabies vaccine: serological and clinical responses of immunized persons to intradermal booster vaccination","volume":"74","author":"Burridge","year":"1984","journal-title":"Am. J. Publ. Health"},{"key":"10.1016\/j.molimm.2017.02.011_bib0045","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa0907650","article-title":"Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine","volume":"361","author":"Clark","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molimm.2017.02.011_bib0050","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.antiviral.2016.09.011","article-title":"The SARE tool for rabies control: current experience in Ethiopia","volume":"135","author":"Coetzer","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.molimm.2017.02.011_bib0055","first-page":"316","article-title":"Comments on the potency testing of rabies vaccines","volume":"21","author":"Crick","year":"1974","journal-title":"Dev. Biol. Stand."},{"key":"10.1016\/j.molimm.2017.02.011_bib0060","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/eji.200838648","article-title":"Alum adjuvanticity: unraveling a century old mystery","volume":"38","author":"De Gregorio","year":"2008","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.molimm.2017.02.011_bib0065","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0264-410X(89)90152-7","article-title":"Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization","volume":"7","author":"Dreesen","year":"1989","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2017.02.011_bib0070","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1586\/14760584.6.4.559","article-title":"Improving vaccines by incorporating immunological coadjuvants","volume":"6","author":"Fraser","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.molimm.2017.02.011_bib0075","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.trivac.2014.04.001","article-title":"DNA vaccination for rabies: evaluation of preclinical safety and toxicology","volume":"3","author":"Garg","year":"2014","journal-title":"Trials Vaccinol."},{"key":"10.1016\/j.molimm.2017.02.011_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7774\/cevr.2015.4.1.1","article-title":"Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases","volume":"4","author":"Grunwald","year":"2015","journal-title":"Clin. Exp. Vaccine Res."},{"key":"10.1016\/j.molimm.2017.02.011_bib0085","doi-asserted-by":"crossref","first-page":"e0003709","DOI":"10.1371\/journal.pntd.0003709","article-title":"Global alliance for rabies control partners for rabies prevention, 2015. Estimating the global burden of endemic canine rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.molimm.2017.02.011_bib0090","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.molimm.2017.02.011_bib0095","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/14760584.6.5.685","article-title":"Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation","volume":"6","author":"Hem","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.molimm.2017.02.011_bib0100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.exppara.2009.11.015","article-title":"Comparison of immune response in sheep immunized with DNA vaccine encoding Toxoplasma gondii GRA7 antigen in different adjuvant formulations","volume":"124","author":"Hiszczy\u0144ska-Sawicka","year":"2010","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.molimm.2017.02.011_bib0105","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.vaccine.2009.01.128","article-title":"Rabies DNA vaccine: no impact of MHC class I and class II targeting sequences on immune response and protection against lethal challenge","volume":"27","author":"Kaur","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2017.02.011_bib0110","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1096\/fj.09-138644","article-title":"Rabies DNA vaccine encoding lysosome-targeted glycoprotein supplemented with Emulsigen-D confers complete protection in preexposure and postexposure studies in BALB\/c mice","volume":"24","author":"Kaur","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.molimm.2017.02.011_bib0115","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1517\/13543784.7.9.1475","article-title":"QS-21: a water-soluble triterpene glycoside adjuvant","volume":"7","author":"Kensil","year":"1998","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.molimm.2017.02.011_bib0120","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1084\/jem.20071087","article-title":"Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells","volume":"205","author":"Kool","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molimm.2017.02.011_bib0125","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.prevetmed.2016.04.015","article-title":"Quantitative risk assessment of the introduction of rabies into Japan through the illegal landing of dogs from Russian fishing boats in the ports of Hokkaido, Japan","volume":"128","author":"Kwan","year":"2016","journal-title":"Prev. Vet. Med."},{"key":"10.1016\/j.molimm.2017.02.011_bib0130","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0264-410X(96)00150-8","article-title":"Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720","volume":"15","author":"Lawrence","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2017.02.011_bib0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jviromet.2013.03.020","article-title":"Evaluation of a non-invasive, inhalational challenge method for rabies vaccine potency assay","volume":"190","author":"Lewis","year":"2013","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.molimm.2017.02.011_bib0140","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jbiotec.2012.08.012","article-title":"The future of human DNA vaccines","volume":"162","author":"Li","year":"2012","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.molimm.2017.02.011_bib0145","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1046\/j.1365-2796.2003.01140.x","article-title":"DNA vaccines: a review","volume":"253","author":"Liu","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.molimm.2017.02.011_bib0150","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.molimm.2004.09.005","article-title":"Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen","volume":"42","author":"Lobaina","year":"2005","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.molimm.2017.02.011_bib0155","series-title":"Laboratory Techniques in Rabies","first-page":"394","author":"Meslin","year":"1996"},{"key":"10.1016\/j.molimm.2017.02.011_bib0160","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1016\/j.vaccine.2004.08.049","article-title":"Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations","volume":"23","author":"Miles","year":"2005","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.molimm.2017.02.011_bib0165","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/tbed.12350","article-title":"Towards canine rabies elimination in cebu, Philippines: assessment of health economic data","volume":"64","author":"Miranda","year":"2015","journal-title":"Transbound. Emerg. Dis."},{"key":"10.1016\/j.molimm.2017.02.011_bib0170","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1586\/erv.11.48","article-title":"Current adjuvants and new perspectives in vaccine formulation","volume":"10","author":"Montomoli","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.molimm.2017.02.011_bib0175","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.vaccine.2004.07.050","article-title":"Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro","volume":"23","author":"Morefield","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2017.02.011_bib0180","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S1878-3317(10)60020-4","article-title":"The role of adjunctive Mycobacterium w immunotherapy for tuberculosis","volume":"2","author":"Nyasulu","year":"2010","journal-title":"J. Exp. Clin. Med."},{"key":"10.1016\/j.molimm.2017.02.011_bib0185","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1016\/j.vaccine.2014.07.040","article-title":"Enhanced immune responses of foot-and-mouth disease vaccine using new oil\/gel adjuvant mixtures in pigs and goats","volume":"32","author":"Park","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2017.02.011_bib0190","first-page":"191","article-title":"Effect of an immunomodulator containing Mycobacterium w on sputum conversion in pulmonary tuberculosis","volume":"100","author":"Patel","year":"2002","journal-title":"J. Indian Med. Assoc."},{"key":"10.1016\/j.molimm.2017.02.011_bib0195","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s13337-015-0285-5","article-title":"Molecular and immunogenic characterization of BHK-21 cell line adapted CVS-11 strain of rabies virus and future prospect in vaccination strategy","volume":"26","author":"Patel","year":"2015","journal-title":"Virusdisease"},{"key":"10.1016\/j.molimm.2017.02.011_bib0200","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.it.2008.09.006","article-title":"New horizons in adjuvants for vaccine development","volume":"30","author":"Reed","year":"2009","journal-title":"Trends Immunol."},{"key":"10.1016\/j.molimm.2017.02.011_bib0205","unstructured":"Romanian Parliament, the law approving Government Ordinance no. 37\/2002 on the protection of animals used for experimental and other scientific purposes (471\/2002) M.Of.R. PI 535\/2002, 2002."},{"key":"10.1016\/j.molimm.2017.02.011_bib0210","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.coi.2011.03.008","article-title":"Electroporation delivery of DNA vaccines: prospects for success","volume":"23","author":"Sardesai","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.molimm.2017.02.011_bib0215","first-page":"2014","article-title":"Dog ecology and barriers to canine rabies control in the republic of Haiti","author":"Schildecker","year":"2016","journal-title":"Transbound. Emerg. Dis."},{"key":"10.1016\/j.molimm.2017.02.011_bib0220","doi-asserted-by":"crossref","first-page":"127","DOI":"10.47276\/lr.76.2.127","article-title":"Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8\u201310 years","volume":"76","author":"Sharma","year":"2005","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.molimm.2017.02.011_bib0225","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0264-410X(91)90309-T","article-title":"Resistance to intravenous inoculation of Mycobacterium tuberculosis H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on Mycobacterium w","volume":"9","author":"Singh","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2017.02.011_bib0230","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.prevetmed.2016.07.015","article-title":"Rabies disease dynamics in na\u00efve dog populations in Australia","volume":"131","author":"Sparkes","year":"2016","journal-title":"Prev. Vet. Med."},{"key":"10.1016\/j.molimm.2017.02.011_bib0235","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijgo.2008.03.021","article-title":"Clinical trial experience with prophylactic HPV 6\/11\/16\/18 VLP vaccine in young women from the Asia-Pacific region","volume":"102","author":"Tay","year":"2008","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.molimm.2017.02.011_bib0240","unstructured":"Three Rs Microsite, 2017. http:\/\/3rs.ccac.ca\/en\/about\/three-rs.html."},{"key":"10.1016\/j.molimm.2017.02.011_bib0245","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1016\/S0264-410X(01)00111-6","article-title":"A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers","volume":"19","author":"Toledo","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2017.02.011_bib0250","article-title":"Some observations related to the validity of potency tests for rabies vaccine","author":"Turner","year":"1974","journal-title":"Symp Ser. Immunobiol Stand."},{"key":"10.1016\/j.molimm.2017.02.011_bib0255","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4236\/wjv.2012.21005","article-title":"Rabies DNA vaccines: current status and future","volume":"2","author":"Ullas","year":"2012","journal-title":"World J. Vaccines"},{"key":"10.1016\/j.molimm.2017.02.011_bib0260","series-title":"WHO Position Paper on Rabies Vaccine: Grading of Scientific Evidence","author":"WHO","year":"2010"},{"key":"10.1016\/j.molimm.2017.02.011_bib0265","series-title":"Global Framework to Eliminate Human Rabies Transmitted by Dogs by 2030","author":"WHO","year":"2016"},{"key":"10.1016\/j.molimm.2017.02.011_bib0270","series-title":"World Health Organization Media Centre","author":"WHO, Rabies","year":"2013"},{"key":"10.1016\/j.molimm.2017.02.011_bib0275","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.282.5388.476","article-title":"Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine","volume":"282","author":"Wang","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.molimm.2017.02.011_bib0280","first-page":"287","article-title":"Immunogenicity and safety of purified Vero-cell rabies vaccine in severely rabies-exposed patients in China","volume":"31","author":"Wang","year":"2000","journal-title":"Southeast Asian J. Trop. Med. Publ. Health"},{"key":"10.1016\/j.molimm.2017.02.011_bib0285","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/0264-410X(91)90188-C","article-title":"The protective role of humoral neutralizing antibody in the NIH potency test for rabies vaccines","volume":"9","author":"Wunderli","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2017.02.011_bib0290","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s12250-013-3321-x","article-title":"Establishment and preliminary application of a rapid fluorescent focus inhibition test (RFFIT) for rabies virus","volume":"28","author":"Yu","year":"2013","journal-title":"Virol. Sin."}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589017300512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589017300512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:29:50Z","timestamp":1758979790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589017300512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":58,"alternative-id":["S0161589017300512"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2017.02.011","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alum adjuvanted rabies DNA vaccine confers 80% protection against lethal 50 LD50 rabies challenge virus standard strain","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2017.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}